Note 4 - Other Financial Information

9 Months Ended

Sep. 30, 2026

Note 4 – Other Financial Information

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following as of September 30, 2026 and December 31, 2025 (in thousands):

	*September 30,*		*December 31,*
	*2026*		*2025*
Accounts payable	$	17,262	$	12,137
Accrued sales reserves		14,936		6,493
Accrued clinical expenses		3,852		2,364
Accrued research and development expenses		1,148		886
Accrued selling, general and administrative expenses		6,312		3,903
Accrued other expenses		3,336		1,934
Total accounts payable and accrued expenses	$	46,846	$	27,717

Interest and Other Income, Net

Interest and other income, net consisted of the following for the three and nine months ended September 30, 2026 and 2025 (in thousands):

	*Three Months Ended September 30,*						*Nine Months Ended September 30,*
	*2026*			*2025*			*2026*			*2025*
Interest income	$	681		$	1,176		$	2,558		$	5,057
Other loss, net		(74	)		(197	)		(744	)		(665	)
Interest and other income, net	$	607		$	979		$	1,814		$	4,392